[A18-06] Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V

Last updated 02.05.2018

Project no.:

Commission awarded on 16.01.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)

Result of dossier assessment:

Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: indication of considerable added benefit. PPMS: indication of lesser benefit than appropriate comparator therapy


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form